Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ivermectin and onchocercal optic neuritis: short-term effects

I Murdoch1, A Abiose, O Babalola

  • 1Department of Ophthalmology, Ahmadu Bello University Teaching Hospital, Kaduna, Nigeria.

Eye (London, England)
|January 1, 1994
PubMed
Summary

Ivermectin, used for onchocerciasis, was studied for its effect on optic neuritis. This trial found ivermectin does not appear to precipitate or worsen optic neuritis within 7-14 days post-treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Provenance of late Pleistocene loess in central and eastern Europe: isotopic evidence for dominant local sediment sources.

Scientific reports·2025
Same author

Using morphometrics to identify sex in the eastern blue-tongued skink (Tiliqua scincoides).

Australian veterinary journal·2023
Same author

Blood product utilisation for coronary artery bypass graft surgery at a public and a private hospital in Western Cape Province, South Africa.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2021
Same author

Correction: Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.

PloS one·2016
Same author

Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.

PloS one·2016
Same author

Haemostatic Abnormalities in Patients with a Clinical Predisposition to Venous Thromboembolism.

Hematology (Amsterdam, Netherlands)·2016

Area of Science:

  • Ophthalmology
  • Infectious Diseases
  • Pharmacology

Background:

  • Onchocerciasis treatment historically used diethylcarbamazine citrate (DEC), which can cause Mazzotti reactions, including optic neuritis.
  • Ivermectin, a macrocyclic lactone, is a widely distributed microfilaricide for onchocerciasis.
  • Limited data exist on ivermectin's impact on active optic neuritis in onchocercal patients.

Purpose of the Study:

  • To evaluate the effect of ivermectin on active optic neuritis in patients with onchocerciasis.
  • To compare the incidence of optic neuritis following ivermectin versus placebo administration.

Main Methods:

  • A large, randomized, double-masked, Phase IV trial involving screening for optic nerve disease (OND).
  • Detailed ophthalmic examinations, including fluorescein angiography, were performed on individuals with suspected OND.

Related Experiment Videos

  • Participants received either ivermectin or placebo, with follow-up examinations and repeat angiograms at 7-14 days.

    • Main Results:

    • Out of 6831 screened individuals, 856 underwent baseline angiography.
    • During follow-up, 6 new cases of active optic neuritis and one exacerbation were identified; 5 received placebo and 1 received ivermectin.
    • Two individuals with pre-existing optic neuritis showed improvement, one on placebo and one on ivermectin.

    Conclusions:

    • Ivermectin does not appear to precipitate or exacerbate active optic neuritis within 7-14 days of treatment.
    • The findings suggest ivermectin is safe concerning optic nerve inflammation in the short term.